Ceragenix and academic partners see positive ceragenin study data
US drugmaker Ceragenix Pharmaceuticals says that one of a family of compounds it is jointly developing with Vanderbilt University in Nashville and Utah's Brigham Young University shows potential virucidal activity in vitro against multiple HIV strains. The compounds, called ceragenins, were invented by Paul Savage at Brigham Young's Department of Chemistry and Biochemistry and are synthetically produced small-molecule drugs capable of electrostatic interaction with certain viruses, fungi and bacteria.
Ceragenix obtained an exclusive license for the product, while its academic partners have jointly filed for a patent on the CSA technology. The company says that it has submitted a 510K application to the Food and Drug Administration seeking clearance to commercialize the technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze